---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-187579"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2023-07-17T23:59:59+00:00"
generated_at: "2026-06-13T07:40:48.312193+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.88
calibrated_materiality_score: 0.88
confidence: "high"
source: SEC EDGAR
---

# Acumen's ACU193 Phase 1 meets endpoints; plaque reduction up to 25%, low ARIA-E rate

## Summary
- 60 mg/kg Q4W cohort showed 25% mean amyloid plaque reduction at day 63; 25 mg/kg Q2W showed 20% at day 70.
- Overall ARIA-E rate 10.4% (5/48); symptomatic ARIA-E 2.1% (1/48); no drug-related serious adverse events.
- Statistically significant dose-proportional PK and near-maximal target engagement of toxic AβOs in CSF.
- Monthly dosing supported by pharmacokinetic and CSF data; company plans FDA interaction in Q4 2023.
- INTERCEPT-AD enrolled 60 early-AD participants; results to be submitted for peer-reviewed publication.

## SEC filing metadata
- accession: 0001193125-23-187579
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2023-07-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.88
- calibrated_materiality_score: 0.88
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000119312523187579/0001193125-23-187579-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000119312523187579/d518971d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-187579
- JSON: https://secwatch.observer/filing/0001193125-23-187579.json
- Plain text: https://secwatch.observer/filing/0001193125-23-187579.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.